Impact of Drug Repurposing on SARS-Cov-2 Main Protease

药物再利用对SARS-CoV-2主蛋白酶的影响

阅读:2

Abstract

The recent emergence of the severe acute respiratory disease caused by a novel coronavirus remains a concern posing many challenges to public health and the global economy. The resolved crystal structure of the main protease of SARS-CoV-2 or SCV2 (M(pro)) has led to its identification as an attractive target for designing potent antiviral drugs. Herein, we provide a comparative molecular impact of hydroxychloroquine (HCQ), remdesivir, and β-D-N(4)-Hydroxycytidine (NHC) binding on SCV2 M(pro) using various computational approaches like molecular docking and molecular dynamics (MD) simulation. Data analyses showed that HCQ, remdesivir, and NHC binding to SARS-CoV-2 M(pro) decrease the protease loop capacity to fluctuate. These binding influences the drugs’ optimum orientation in the conformational space of SCV2 M(pro) and produce noticeable steric effects on the interactive residues. An increased hydrogen bond formation was observed in SCV2 M(pro)–NHC complex with a decreased receptor residence time during NHC binding. The binding mode of remdesivir to SCV2 M(pro) differs from other drugs having van der Waals interaction as the force stabilizing protein–remdesivir complex. Electrostatic interaction dominates in the SCV2 M(pro)−HCQ and SCV2 M(pro)–NHC. Residue Glu166 was highly involved in the stability of remdesivir and NHC binding at the SCV2 M(pro) active site, while Asp187 provides stability for HCQ binding.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。